Etoposide-based combination chemotherapy in malignant histiocytosis

Abstract

We investigated the responses of patients with malignant histiocytosis (MH) to the treatment of epotoside-based regimen. Of 11 evaluable cases, 9 (81.8%) achieved complete remission and 1 partial remission. 7 complete remission cases (77.7%) received only one therapeutic course. The side effects were mild and welltolerated. We conclude that etoposide-containing regimen is highly effective and can be used as first-line treatment for MH and is worthy of further study.

Keywords

etoposide combination chemotherapy malignant histiocytosis

References

[1] 1992;352–357

[2] TsengA, ColemanC N, CoxR S, et al. . The treatment of malignant histiocytosis. Blood, 1984, 64: 48-48

[3] ZuckerJ M, CaillauxJ M, VanelD, et al. . Malignant histiocytosis in childhood: Clinical study and therapeutic results in 22 cases. Cancer, 1980, 45: 2821-2821

[4] VP16, 1989, 12, 8

[5] VogelzangN J, RaghavanD, KennedyB J. VP-16-213 (etopiside): The mandrake root from Essyk-Kul. Am J Med, 1982, 72: 136-136

[6] RoweJ M, ChangA Y C, BennettJ M. Aclacinomycin A and etoposide CVP-16-213): An effective regimen in previously treated patients with refractory acute myelogenous leukemia. Blood, 1988, 71: 992-992

[7] SeljelidR, EskelandT. The biology of macrophages: In general principles and properties. Eur J Haematol, 1993, 51: 267-267